Ketelhut R, Messerli F H
Department of Internal Medicine, Ochsner Clinic, New Orleans, Louisiana.
Prim Care. 1991 Sep;18(3):577-92.
Left ventricular hypertrophy (LVH) has been identified as a significant risk factor for future cardiovascular morbidity and mortality. LVH and its sequelae such as myocardial ischemia, impaired filling and contractility, ventricular arrhythmias, and congestive heart failure can be reduced by specific antihypertensive agents. Future clinical trials will determine whether a reduction of LVH will ultimately improve its inherent ominous prognosis.
左心室肥厚(LVH)已被确认为未来心血管疾病发病和死亡的重要危险因素。特定的抗高血压药物可以减轻LVH及其后遗症,如心肌缺血、充盈和收缩功能受损、室性心律失常以及充血性心力衰竭。未来的临床试验将确定LVH的减轻是否最终会改善其固有的不良预后。